Paolo Casali

Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?

A new journal... on spindle cells.

Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.

Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity.

Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEmu enhancer and 3'Ealpha enhancers in human lymphoblastoid B cells.

Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

A role for the MutL mismatch repair Mlh3 protein in immunoglobulin class switch DNA recombination and somatic hypermutation.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Reduced tetanus antibody titers in overweight children.

DNA repair in antibody somatic hypermutation.

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).

Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution.

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure.

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.

DNA replication to aid somatic hypermutation.

Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation.

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates.

Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.

Chordoma.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.

Combined modalities approach for localized adult extremity soft-tissue sarcoma.

Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination.

Molecular mechanisms of autoimmunity.

A role for DRAK2 in the germinal center reaction and the antibody response.

The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution.

The consensus statement on the locoregional treatment of abdominal sarcomatosis.

Nature and functions of autoantibodies.

AID- and Ung-dependent generation of staggered double-strand DNA breaks in immunoglobulin class switch DNA recombination: a post-cleavage role for AID.

Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients.

Stem cell transplantation in autoimmune diseases. Foreword.

Lupus-prone MRL/faslpr/lpr mice display increased AID expression and extensive DNA lesions, comprising deletions and insertions, in the immunoglobulin locus: concurrent upregulation of somatic hypermutation and class switch DNA recombination.

Response to sunitinib malate in advanced alveolar soft part sarcoma.

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.

Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma.

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS).

HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation.

Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Translocation-related sarcomas.

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.

International collaborations in cancer control and the Third International Cancer Control Congress.

Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival.

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control.

Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.

Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.

Trabectedin therapy for sarcomas.

Do rare cancers deserve specific strategies for cancer research?

PML down-regulation in soft tissue sarcomas.

Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution.

14-3-3 adaptor proteins recruit AID to 5'-AGCT-3'-rich switch regions for class switch recombination.

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

Specific cross-reaction of anti-dsDNA antibody with platelet integrin GPIIIa49-66.

Estrogen receptors bind to and activate the HOXC4/HoxC4 promoter to potentiate HoxC4-mediated activation-induced cytosine deaminase induction, immunoglobulin class switch DNA recombination, and somatic hypermutation.

Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.

Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.

A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.

Endonuclease G plays a role in immunoglobulin class switch DNA recombination by introducing double-strand breaks in switch regions.

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.

Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.

Systemic therapy options for unresectable and metastatic chordomas.

AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4.

PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava.

Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.

Uterine sarcomas: a multidisciplinary challenge.

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.

Rare cancers are not so rare: the rare cancer burden in Europe.

Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Phase II study of imatinib in advanced chordoma.

BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway.

Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or 2 faces of the same disease?

Iron inhibits activation-induced cytidine deaminase enzymatic activity and modulates immunoglobulin class switch DNA recombination.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

B cell TLRs and induction of immunoglobulin class-switch DNA recombination.

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Adjuvant therapy of gastrointestinal stromal tumors (GIST).

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Evicase: an evidence-based case structuring approach for personalized healthcare.

Automatic detection of inconsistencies between free text and coded data in Sarcoma discharge letters.

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.

Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.

Rev1 recruits ung to switch regions and enhances du glycosylation for immunoglobulin class switch DNA recombination.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

APRIL stimulates NF-κB-mediated HoxC4 induction for AID expression in mouse B cells.

Regulation of Aicda expression and AID activity.

Role of macrophage targeting in the antitumor activity of trabectedin.

Improving methodology to go beyond histology in rare cancers.

Analyzing the "CareGap": assessing gaps in adherence to clinical guidelines in adult soft tissue sarcoma.

Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients.

The intriguing patterns of tumor response to trabectedin.

Epigenetics of the antibody response.

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.

Myxoid liposarcoma and the mammalian target of rapamycin pathway.

Localised thoracic sarcomas: outcome improvement over time at a single institution.

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Adjuvant therapy for high-risk soft tissue sarcoma in the adult.

Induction of activation-induced cytidine deaminase-targeting adaptor 14-3-3γ is mediated by NF-κB-dependent recruitment of CFP1 to the 5'-CpG-3'-rich 14-3-3γ promoter and is sustained by E2A.

Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.

Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS.

MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.

Combinatorial H3K9acS10ph histone modification in IgH locus S regions targets 14-3-3 adaptors and AID to specify antibody class-switch DNA recombination.

TSPAN33 is a novel marker of activated and malignant B cells.

Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination.

Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.

Policy statement on multidisciplinary cancer care.

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.

Emerging therapies for adult soft tissue sarcoma.

Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors.

MicroRNAs in lupus.

Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.

Type II Toxoplasma gondii induction of CD40 on infected macrophages enhances interleukin-12 responses.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection.

Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses.

Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses.

Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.

High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.

Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.

B cell Rab7 mediates induction of activation-induced cytidine deaminase expression and class-switching in T-dependent and T-independent antibody responses.

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.

Response of conventional chondrosarcoma to gemcitabine alone: a case report.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.

Adjuvant chemotherapy for soft tissue sarcoma.

Hope in cancer patients: the relational domain as a crucial factor.

The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).

Understanding Deviations from Clinical Practice Guidelines in Adult Soft Tissue Sarcoma.

Imatinib in advanced chordoma: A retrospective case series analysis.

Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Regulation of B Cell Differentiation by Intracellular Membrane-Associated Proteins and microRNAs: Role in the Antibody Response.

Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.

Adjuvant Imatinib for GI Stromal Tumors: When and For How Long?

Genome-Wide Analysis Reveals Selective Modulation of microRNAs and mRNAs by Histone Deacetylase Inhibitor in B Cells Induced to Undergo Class-Switch DNA Recombination and Plasma Cell Differentiation.

Epigenetics of Peripheral B-Cell Differentiation and the Antibody Response.

Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group.

Editorial: Epigenetics of B Cells and Antibody Responses.

External validation of a multi-institutional retroperitoneal sarcoma nomogram.

Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.

Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.

Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.

Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum.

Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review.

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Small Molecule Inhibition of Rab7 Impairs B Cell Class Switching and Plasma Cell Survival To Dampen the Autoantibody Response in Murine Lupus.

Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair.

Advances and controversies in the management of soft tissue sarcomas.

ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review.

Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.

Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group.

Rad52 competes with Ku70/Ku86 for binding to S-region DSB ends to modulate antibody class-switch DNA recombination.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Correction: Scaffold Functions of 14-3-3 Adaptors in B Cell Immunoglobulin Class Switch DNA Recombination.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma.

Improving treatment results with reference centres for rare cancers: where do we stand?

Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group.

Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.

Neoadjuvant treatment: a novel standard?

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions.

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.